Systemic lupus erythematosus
Education on Systemic lupus erythematosus and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Systemic lupus erythematosus and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Systemic lupus erythematosus?
Systemic lupus erythematosus is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Autoimmune conditions involve the immune system attacking the body's own tissues. Mark Egly's patent links many autoimmune diseases to low Alpha-1 Antitrypsin (AAT) or Alpha-1 Antitrypsin Deficiency (AATD) and excess neutrophil activity.
What Mark Egly's patent discusses
A large number of autoimmune diseases occur because the body's homeostasis is altered by an overabundance of neutrophils or neutrophil elastase ("NE"). The level of neutrophils in the body can be controlled through administration of or supplementation with AAT. A diagnosis of an autoimmune disease may be indicative of AATD or an insufficient level of AAT without being AATD. By identifying lower or deficient AAT levels improved disease control can be realized through administration of or supplementation with AAT. In addition, patients will experience less inflammation as a result of the administration of, or supplementation with AAT. With reduced inflammation, need for aspirin and similar products to relieve pain will be reduced and potential liver disease and other conditions associated wi
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Systemic lupus erythematosus, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Systemic lupus erythematosus, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: